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Abstract
Background
Human papillomavirus (HPV) has proven to be the cause of several severe clinical condi-
tions on the cervix, vulva, vagina, anus, oropharynx and penis. Several studies have
assessed the costs of cervical lesions, cervical cancer (CC), and genital warts. However,
few have been done in Africa and none in Swaziland. Cost analysis is critical in providing
useful information for economic evaluations to guide policymakers concerned with the allo-
cation of resources in order to reduce the disease burden.
Materials and methods
A prevalence-based cost of illness (COI) methodology was used to investigate the eco-
nomic burden of HPV-related diseases. We used a top-down approach for the cost associ-
ated with hospital care and a bottom-up approach to estimate the cost associated with
outpatient and primary care. The current study was conducted from a provider perspective
since the state bears the majority of the costs of screening and treatment in Swaziland. All
identifiable direct medical costs were considered for cervical lesions, cervical cancer and
genital warts, which were primary diagnoses during 2015. A mix of bottom up micro-costing
ingredients approach and top-down approaches was used to collect data on costs. All costs
were computed at the price level of 2015 and converted to dollars ($).
Results
The total annual estimated direct medical cost associated with screening, managing and
treating cervical lesions, CC and genital warts in Swaziland was $16 million. The largest
cost in the analysis was estimated for treatment of high-grade cervical lesions and cervical
cancer representing 80% of the total cost ($12.6 million). Costs for screening only repre-
sented 5% of the total cost ($0.9 million). Treatment of genital warts represented 6% of the
total cost ($1million).
PLOS ONE | https://doi.org/10.1371/journal.pone.0177762 May 22, 2017 1 / 16
a1111111111
a1111111111
a1111111111
a1111111111
a1111111111
OPENACCESS
Citation: Ginindza TG, Sartorius B, Dlamini X,
O¨stensson E (2017) Cost analysis of Human
Papillomavirus-related cervical diseases and genital
warts in Swaziland. PLoS ONE 12(5): e0177762.
https://doi.org/10.1371/journal.pone.0177762
Editor: Marcia Edilaine Lopes Consolaro,
Universidade Estadual de Maringa, BRAZIL
Received: January 20, 2017
Accepted: May 3, 2017
Published: May 22, 2017
Copyright: © 2017 Ginindza et al. This is an open
access article distributed under the terms of the
Creative Commons Attribution License, which
permits unrestricted use, distribution, and
reproduction in any medium, provided the original
author and source are credited.
Data Availability Statement: Data from this study
are the property of the Government of Swaziland
and University of KwaZulu-Natal and cannot be
made publicly available. All interested readers can
access the data set from the Secretariat SEC
Committee (Swaziland Scientific and Ethics
Committee) and University of KwaZulu-Natal
Biomedical Research Ethics Committee (BREC)
from the following contacts: The Chairman
Scientific and Ethics Committee Ministry of Health,
Swaziland P.O. Box 5 Mbabane, H1 Tel: (+268)
2404 231 Fax: (+268) 2404 2092. The Chairperson
BIOMEDICAL RESEARCH ETHICS
Conclusion
According to the cost estimations in this study, the economic burden of HPV-related cervical
diseases and genital warts represents a major public health issue in Swaziland. Prevention
of HPV infection with a national HPV immunization programme for pre-adolescent girls
would prevent the majority of CC related deaths and associated costs.
Introduction
Human papilloma virus (HPV) infection and specifically oncogenic HPV types 16 and 18 are
highly associated with cervical abnormalities and invasive cervical cancer and other diseases
on the cervix, vulva, vagina, anus, oropharynx and penis, all of which impact on people´s
health and resource consumption in society [1]. According to the published literature, the cost
for screening, management and treating patients with HPV-related diseases is related to the
high health care costs and is suggested to be greater than the combined cost for the prevention
and treatment of most prevalent sexually transmitted diseases (STIs) [2].
While screening methods advance and HPV vaccination introduction efforts gain momen-
tum, information on the current evidence on the effectiveness of prevention methods is essen-
tial to reinforce further development and expansion of programmes [3]. Currently, the
common prophylactic vaccines for cervical cancer target most prevalent oncogenic types of
HPV 16 and 18, with nearly 100% type-specific protection [3, 4]. Two HPV vaccines have been
available since 2006, the quadrivalent HPV vaccine (HPV-4) (Gardasil, Merck) [5] and the
bivalent HPV vaccine (HPV-2) (Cervarix with AS04, GlaxoSmithKline) [4, 6]. The HPV-4 vac-
cine also targets non-oncogenic HPV types 6 and 11, which are the cause of genital warts [5].
Studies have demonstrated that both vaccines have more than 70% efficacy against the inci-
dence of high-grade squamous intraepithelial lesion (HSIL), if administered to previously
unexposed women [5–11]. Recently, nonavalent vaccine (HPV-9) targeting seven HPV types
(HPV16/18/31/33/45/52/58) that contribute to 90% of cervical cancer cases plus HPV-6/11 has
been licensed and recommended, based on evidence of vaccine efficacy and immunogenicity
[12, 13]. HPV vaccination is now considered to be the primary form of cervical cancer preven-
tion [4, 14].
In most health economic studies related to cervical cancer prevention in low-income coun-
tries (LIC), data have been reported as part of the bigger picture of the cost-effectiveness analy-
ses [15–19]. Other costing research done in the LIC reported information on cervical cancer
screening and diagnosis, but there are very few reports on treatment for cervical intraepithelial
neoplasia (CIN), invasive cervical cancer (ICC) [20–22] and genital warts [23]. The estimated
societal cost of non-carcinogenic HPV disease such as genital warts is also essential to establish
the health sector budget since 32 million people are affected by genital warts annually and 90%
of these are related to HPV6/11 [24]. Most of the cost analysis on HPV-related diseases have
been done in the high-income and, middle-income countries and very few in the low-income
countries, especially in Africa [25–29]. Such studies are critical in providing useful information
for policymakers in low-resource countries concerned with the allocation of scarce resources
to reduce the burden from HPV among the whole population [20]. However, to date there are
no published studies for the Kingdom of Swaziland. To invest in public interventions for HPV
immunization, it is essential to know the human and economic burden of HPV-related condi-
tions. Estimates of the economic burden of a disease for a given period are useful for under-
standing the relative economic magnitude of a health problem [30]. The principal component
Cost of Human Papillomavirus diseases in Swaziland
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of health economic analyses is cost analysis and it has direct implications for the cost-effective-
ness analyses used for decisions of resource allocation for public health interventions [15, 31].
Therefore, the economic burden of HPV-related conditions needs to be further investigated
and the present study is the first in Swaziland to estimate the cost of HPV-related conditions
such as cervical lesions, cervical cancer and genital warts.
Materials and methods
Study area
The Kingdom of Swaziland is a small, independent, low-resource nation in Southern Africa. It
covers an area of 17,364 km 2 and is landlocked, with Mozambique to its east and South Africa
to its north, west, and south [32, 33] It is divided into four political regions (Hhohho, Manzini,
Shiselweni and Lubombo) (Fig 1) [33]. The 2007 population and housing census estimated the
population of Swaziland to be 1 018 449, with 537 021 females, including a figure of 126 616
aged between 30 and 59 years [34]. Swaziland’s currency is pegged to the South African rand,
effectively relinquishing Swaziland’s monetary policy to South Africa [35]. The government is
heavily dependent on customs duties from the Southern African Customs Union (SACU), and
worker remittances from South Africa supplement domestically earned income [35]. Swazi-
land’s GDP per capita makes it a lower middle-income country, but its income distribution is
highly skewed, with an estimated 20% of the population controlling 80% of the nation’s wealth
[35]. The GDP per Capita in Swaziland is equivalent to 32 percent of the world’s average. GDP
per capita in Swaziland averaged $2598.20 from 1970 until 2015, reaching an all-time high of
4057.28 USD in 2015 [35, 36]. As of 2014, more than one-quarter of the adult population was
infected by HIV/AIDS; Swaziland has the world’s highest HIV prevalence rate [35, 37].
Fig 1. Map showing the location and political regions of Swaziland. Source: Macmillan. Geography and map of
Swaziland Matsapha2005 [accessed 2012]. Available from: http://geography.about.com/library/blcswaziland.htm.
https://doi.org/10.1371/journal.pone.0177762.g001
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Additionally, the burden of high-risk HPV (hr-HPV) infection is high (46.2%), corresponding
to 174,046 women (aged between 15 and 49 years old) in the country [38]. Currently, HPV
testing is not part of both screening and management strategies. In addition, HPV immuniza-
tion programme is not available in Swaziland. Furthermore, cancer patients are referred to
South Africa for cancer staging and cancer treatment (chemotherapy, radiotherapy and
brachytherapy) because such services are not available in Swaziland.
Cost-of-illness
From the provider perspective we performed a cost-of-illness study which is a commonly used
methodology to investigate the economic burden of diseases [39]. It´s a descriptive type of
analysis estimating specific disease related costs and gives information on where these costs
occur in a society. In addition, cost-of illness studies gives important reference data for eco-
nomic evaluations for further guidance on how to allocate resources to improve resource effi-
ciency. Economical evaluations are important for health policy makers when planning
decisions regarding budget. An example could be the estimated cost a given country spends
per year on caring for patients with cervical cancer. With an increased prevalence of HPV, the
number of cervical cancer patients will increase and it´s important to plan for increased costs
and interventions to reduce disease burden. Cost-of-illness studies are performed by using
either the incidence or prevalence basis. Incidence-based approaches are usually used to esti-
mate the life-time costs for a patient, from diagnosis to cure or death useful to estimate the
effect of a specific treatment on future costs. The prevalence-based method considers all costs
for a patient population in a geographical area for a given time period. The prevalence-based
method has been previously used in for Sweden investigating costs for HPV-related cervical
diseases and genital warts [40]. From this methodology, we used a top-down approach for the
costs associated with health care performed at the hospital and a bottom-up approach to deter-
mine costs associated with primary care. Our study population were females diagnosed with
cervical cancer, cervical lesions and genital warts.
Cost data
We investigated only direct medical costs, which were divided into recurrent costs and capital
costs [18]. Recurrent costs included personnel, travel, consumables/supplies (medical and
non-medical), administration, utilities and overheads, while capital costs made up of equip-
ment, buildings, vehicles and any other cost item with a useful life of more than one year and
with an equivalent value of $50. All costs were computed at the 2015 price level and converted
to dollars ($). All costs for screening and management of high-grade cervical lesions (HSIL)
and genital warts were based on sources presented in Table 1.
Cervical lesions
In Swaziland, the following two approaches are currently used to detect the precancerous or
cancerous cells on the cervix and management of cervical lesions: (1) Pap smear and if HSIL is
detected it is followed by treatment with loop electrode excision procedure (LEEP) or total
adnominal hysterectomy (TAH), and (2) the “Screen-and-Treat” approach using VIA followed
by treatment with cryotherapy and LEEP [43]. Data on the number of cytological/Pap results
or number of women screened by Pap smear (i.e. results that could be determined, including
normal or abnormal results) and inadequate cytological results (i.e. results that could not be
determined) were obtained from the Annual National Sexual and Reproductive Health pro-
gramme report, 2015 [44], and the Health Management Information System (HMIS) report
[45]. To estimate the burden of HSIL we used survey weights to extrapolate sample
Cost of Human Papillomavirus diseases in Swaziland
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proportions to population totals based on the 2007–2030 population projections aligned to the
estimated 2014 population [46]. The cervical cancer screening guidelines provided informa-
tion on the management of abnormal cytological results, treatment procedures for women
with histologically confirmed HSIL or worse (HSIL+) [43]. As per the guidelines, it was
assumed that women with abnormal cytological results were referred to a gynaecologist for an
immediate biopsy and histologically confirmed CIN2+, and had one follow-up visit to undergo
loop electrode excision procedure (LEEP) or total adnominal hysterectomy (TAH), which are
the most common treatment currently utilized in health care facilities in Swaziland. No treat-
ment procedure was included for women with LSIL, as the recommendations state that further
follow-up should be performed every 6 months until the lesion regresses to normal or there is
evidence of progression [43]. One follow-up procedure with Pap smear and antibiotics was
therefore assumed to have been performed within the year of follow-up.
Table 1. Data variables and source for costs regarding screening, management and treatment of cervical lesions, cervical cancer and genital
warts.
Data /Parameter Source Prices source
Estimated numbers of cervical cancer cases
Total number of cervical cancer 220
cases
Swaziland National Cancer Registry (SNCR), Ministry of Health), Report On
Cases Of Cancers In Swaziland (2014–2015)
Screening
VIA screened Monitoring &Evaluation, Strategic Information Department, Ministry of Health:
Annual National Sexual and Reproductive Health programme report, 2015,
Pages 15–16
Health Management Information System (HMIS)
Market price
Pap smeara Monitoring &Evaluation, Strategic Information Department, Ministry of Health:
Annual National Sexual and Reproductive Health programme report, 2015,
Pages 15–16
Health Management Information System (HMIS
Private hospital or Market price
[41]
Lesions and cancer diagnosis and treatment
Treatment with LEEPd Raleigh Fitkin Memorial (RFM) hospital-Theatre records review Market price [41]
Treatment with cryotherapy (VIA
positives)b
Monitoring &Evaluation Ministry of Health Market price [41]
Follow up with Pap smear and
antibiotics of LSIL
Mbabane gynaecologist (Interview) Market price [41]
Treatment of HSIL-FIGO I with
hysterectomy
Mbabane Government and Mbabane Clinic private gynaecologists (Interviews) Private: The clinic or Market
price [41]
Treatment of FIGO II-IV with
radiotherapy and chemotherapy
Phalala Fund and South African private hospitals charges Phalala and Life Hospital
(Oncology unit: Radiology [42]
Biopsyc Health Management Information System (HMIS) Private hospital or Market price
[41]
Genital warts
Wart removal with cauterization Theatre records review (Mbabane Government hospital, Piggs Peak hospital,
RFM, Mankayane hospital, Good Shepard Hospital, Hlathikhulu Hospital).
Reported by the Gynaecologists from these hospitals
Private Hospital or Market price
[41]
Wart removal with podophyllotoxin
and antibiotics
Mbabane gynaecologist and cancer screening clinic (Interview) Market price [41]
a: The costs for Pap smear included nurse assessment, laboratory costs, physician assessment of abnormal results and test costs.
b: The cost for ‘see-and-treat approach included VIA testing, nurse assessment of the abnormal results, and cryotherapy treatment of the VIA positive test
results.
c:The cost for biopsy included laboratory costs, physician assessment of abnormal results.
d: Costs for LEEP and TAH included physician assessment, operation cost, anaesthesia and antibiotics.
NB: Costs for the treatment variables were then taken from the private hospitals in Swaziland and South Africa, which were based on the market price.
https://doi.org/10.1371/journal.pone.0177762.t001
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In 2009, the Swazi Ministry of Health integrated the “see-and-treat” approach using VIA
followed by treatment with cryotherapy for the national cervical cancer prevention pro-
gramme to accelerate the early detection of cervical lesions. Data on the number of VIA
screened and VIA positives were obtained from Annual National Sexual and Reproductive
Health programme report [44]. The total number of women treated with LEEP was retrieved
from the Raleigh Fitkin Memorial (RFM) Hospital theatre records from2015.
Cervical cancer
The resources used to calculate the treatment costs for cervical cancer were based on the Pha-
lala fund scheme report [47], and the breakdown of the treatment variables was influenced by
a Swedish study [48]. Costs for the treatment variables were then taken from the private hospi-
tal in South Africa, which were based on the market price [42]. These costs included diagnosis,
staging, and full treatment of cervical cancer divided into the different cancer stages, pharma-
ceuticals, and transportation cost of patients from Swaziland to South Africa. Due to the lack
of official data, the proportion of women treated for different International Federation of
Gynecology and Obstetrics (FIGO) stages of cancer, was based on the empirical number of
patients diagnosed and treated according to the cancer registry situational analysis report [49],
as well as the Phalala report [47].
Direct medical costs of visits for treatment of large warts which included diathermy, cauter-
ization, or surgical excision, were estimated at market price and based on private hospital char-
ges. Costs for podophyllotoxin and antibiotics treatments were estimated at the market cost.
To obtain the overall costs of genital warts, we used the estimated percentage of people who
had related procedures or visit hospitals, multiplied by the relevant number of cases of genital
warts (i.e. number of people treated with cauterization). This number was then calculated by
multiplying the cost of the treatment or visit, including the cost of podophyllotion applied by a
gynaecologist/nurse at the site care and one course of antibiotic.
According to the Report On Cases Of Cancers In Swaziland, a total of 440 cervical cancer
cases were diagnosed between 1 January 2014 and 31st December 2015 [49]. The sources of
information for this report were government, private hospitals and the Hospice At Home and
death certificates stating cervical cancer as the contributory cause of death. To estimate the
total number of cervical cancer cases for the year 2015, we divided the 440 by 2. Therefore, for
our analysis, we used the average prevalent number of 220 cervical cancer cases in Swaziland.
We assumed that the reported number of women diagnosed with cervical cancer were clini-
cally staged according to FIGO staging procedures, and treated as per cervical cancer guide-
lines [43] the same year that they were diagnosed. The size of growth of the cancer is assessed
clinically and supplemented by a limited of investigations (cystoscopy, cone biopsy, endocervi-
cal curettage or smear, X-ray or CT scan). Some tests for staging such as MRI are not available
in the country and patients are transferred to South Africa for all treatment of invasive cervical
cancer (radiotherapy, chemotherapy, and surgery), performed in South African private hospi-
tals. Therefore, all costs for treatment were based on the private hospital charges.
Genital warts
Due to lack of an STI surveillance system being in place, no reliable prevalence data were
obtained. Therefore, epidemiological data from the current study (not yet published but under
review by Infectious Agent and Cancer Journal) were used to estimate the actual population
burden of genital warts in women of reproductive age (15–49 years). In the current study, we
used survey weights to extrapolate sample proportions to population totals, based on the
2007–2030 population projections aligned to the estimated 2014 population (15–49 years)
Cost of Human Papillomavirus diseases in Swaziland
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[46]. To calculate the cost we used the estimated population burden of genital warts obtained
from our study. These estimates were deemed the best available evidence to estimate the com-
prehensive burden of genital warts in Swaziland, in respect of prevalent cases, persistence, and
recurrence among the population. In Swaziland, genital warts are treated based on the WHO
guidelines for management of STIs [50]. During data collection, gynaecologists and nurses
with extensive clinical experience in managing and treating patients with genital warts were
interviewed. Small genital warts are treated with podophyllotoxin and antibiotics and large
warts are removed by cauterization at the hospital theatre.
Ethical consideration
The study was approved by the Swaziland Scientific Ethics Committee (MH599C/FW00015267/
IRB0009688) and the Biomedical Research Ethics Committee of the University of KwaZulu-
Natal (BE 242/14).
Results
Cervical lesions
In 2015 the National Sexual and Reproductive Health programme and Health Management
Information System reported a total of 20 009 women screened, of which 8229 (41.1%) were
cytological tests (Pap smear), 11 248 (56.2%) were VIA screened and 532 (2.7%) had a biopsy
[44]. Of the total screened, 16 496 (82.4%) were abnormal results. The report did not provide
the number of those who were HSIL. To estimate the burden of HSIL (actual number of
HSIL), we used survey weights to extrapolate sample proportions to population totals based on
the 2007–2030 population projections aligned to the estimated 2014 population [46]. The col-
lection of data on costs resulted in cost estimations for precancerous lesions and genital warts
presented in Table 2.
Cervical cancer
Table 3 shows the breakdown for the staging and treatment variables for FIGO 1–4 (total num-
ber of sessions per stage). According to the Swaziland National Cancer Registry (SNCR), there
were 220 number cervical cancer cases during 2015 in the country [49]. The treatment period
was assumed to occur within the same 1 year as the staging. Staging included a clinical exami-
nation with cystoscopy during anaesthesia, performed in South Africa. FIGO stages 1a1-1b1
were assumed to be treated with surgery alone (i.e. hysterectomy) in Swaziland and no trans-
port or lodging was therefore estimated. In FIGO stage 1b2-5, the patients were assumed to be
treated with brachytherapy, radiotherapy and chemotherapy during the 5 weeks and therefore
lodging was assumed for 35 days. The difference in treatment between FIGO stage 3 and
FIGO stage 4 was due to the fact that, the dissemination of disease in stage 4 needed limited
brachytherapy.
Table 4 shows the costs for staging, management and treatment of cervical cancer per FIGO
stages. Including costs in the breakdown variables resulted in a cost of $6 405 for FIGO 1a1-
1b1 and between $25 527 and $23 923 for FIGO 1b2-4. Less costly was FIGO stage 4 due to
less brachytherapy.
The total annual cost for cervical cancer was estimated at $5 million (ranging from $3.8 mil-
lion to $6.3 million) based on estimates of 10% of patients in FIGO stage Ia1-Ib1, 10% in FIGO
stage Ib2-II, 50% in FIGO stage 3 and 30% in FIGO stage 4 (Table 5).
Cost of Human Papillomavirus diseases in Swaziland
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Genital warts
The total number of prevalent cases of genital warts (seeking or receiving treatment) in Swazi-
land was estimated to be 6 111 in 2015 (Table 5). The estimated costs for management and
treatment of genital warts were almost $1.1 million of which topical medicines represented the
majority of the $0.9 million. Treatment with cauterization represented only a minor cost.
Table 3. Breakdown for staging and treatment variables for FIGO stage 1–4.
Variables 1a1-1b1 1b2-2 3 4
Transport 1 1 1
Lodging 35 35 35
Hospital admission 1 1 1 1
Total adnominal hysterectomy with anaesthesia 1 - - -
Clinical examination with cystoscopy with anaesthesia 1 1 1 1
Brachytherapy treatment - 3 2 -
Radiotherapy treatment - 25 25 25
Follow up during treatment - 2 2 2
Chemotherapy - 6 6 6
Follow-up during chemotherapy - 1 1 1
Follow-up of treatment 1 12 12 12
MRI 1 1 1 1
https://doi.org/10.1371/journal.pone.0177762.t003
Table 2. Costs for prevention, management and treatment for cervical lesions and genital warts expressed in $ 2015.
Parameter Variables included in the cost Cost
($)
Pap smear screens Examination table with foot supports, examination light, speculum, examination gloves, cervical spatula and
cytobrush glass slide and fixative, time
22
Total VIA screened Nurse’s time, examination table, speculum, light source (halogen torch or flashlight), instrument tray, 3 cotton
swabs, examination gloves, 20mls of 3% to 5% acetic acid (white table vinegar) solution
53
Biopsy Colposcope: Variable fixed power or zoom lens (3× to 7× low power to 15× to 40× high power), biopsy forceps,
endocervical curette (Kevorkian curette, no basket), endocervical speculum (Kogan, both narrow and wide types),
ring forceps, tenaculum (rarely used), cervical hook (rarely used), Pap smear materials, vaginal speculums, full-
strength Lugol’s iodine solution, Monsel’s solution (ferric subsulfate), 1 mL, Acetic acid solution 3% to 5% (white
vinegar; 4–6 oz or 120–180 mL), cotton- or rayon-tipped swabs (8–10),junior Scopettes/OB-GYN applicators (6–
10)
4 × 4 gauze, urine or sputum cups for vinegar, vaginal side wall retractor, underpads ("chuck pads") (17 × 24 inch),
Cotton balls (15–20)
Power (electricity), Dr’s time, Lab cost
58
LEEP Usage of all equipment/instruments, linen and consumables: 1 packet of cotton balls, 1 packet gauze, antiseptic
solutions –Savlon ±50cc, floor cleaning solution-sonic 1backet, specimen bottle, formalin 10cc, Cidex solution 5L,
vinegar solution, anesthesia, doctor and nurse’s time
2 049
Cryotherapy Usage of cryotherapy machine and equipment, Nitrous oxide, sanitary pad, detergents (95% alcohol, water,
sodium chloride solution, Nurse’s time
Antibiotics treatment: Amoxylin/ciproflaxin 500mg BID, Flagyl 400mg tid 7/7 days
OR: Panado 1gm TDS and Diclofenac 50mg TDS 3/7 days
96
Follow up procedure of
LSIL
With Pap smear and antibiotics. 52
Treatment of HSIL With hysterectomy during anesthesia: Usage of equipment/instruments, linen, 5 swabs abdominal packs, 20
gauges, Sutures –4 vicryl No.2 and 2 vicryl No.1, anesthesia, doctor and nurse
3 941
Wart removal with
cauterization
Usage of diathermy machine/instruments, linen, antibiotics, 5 abdominal swaps, sutures 2 948
Wart removal with topical
cream
Silver nitrate pencil, gauze, podophyllotoxin, antibiotics, nurse’s time 161
https://doi.org/10.1371/journal.pone.0177762.t002
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Total annual estimated cost
The estimated total annual cost of prevention and health care with cervical screening was $0.9
million (ranging between $0.6 million and $1.1million), while management and treatment of
cervical lesions was estimated at $9 million (ranging between $6.7 million and $11.3 million),
Table 4. Costs for staging, management and treatment of cervical cancer per FIGO stage 1–4 presented in USD ($) 2015.
Staging and treatment variables Cost ($) 1a1-1b1 1b2-2 3 4
Transport 236 236 236 236
Lodging 22 765 765 765
Hospital admission 591 591 591 591 591
Total adnominal hysterectomy with anaesthesia 5 517 5 517
Clinical examination with cystoscopy with anaesthesia 660 660 660 660
Brachytherapy treatment 535 1 605 1 070
Radiotherapy treatment 535 13 371 13 371 13 371
Follow-up during brachytherapy and radiotherapy 296 593 593 593
Chemotherapy 514 3 083 3 083 3 083
Follow-up during chemotherapy 296 296 296 296
Follow-up after and during treatment 296 296 3 557 3 557 3 557
MRI 771 771 771 771
Total 6 405 25 527 24 992 23 923
https://doi.org/10.1371/journal.pone.0177762.t004
Table 5. Annual cost estimation for prevention, management and treatment of cervical lesions, cancer and genital warts expressed in $ 2015.
Parameter Prevalence 2015 Cost per item Base case cost Range
Number $ 2015 $ 2015 Lower (-50%) Higher (+50)
Screening
Pap smear 8 229 22 180 301 90 150 270 451
Total VIA screened 11 248 53 601 050 300 525 901 576
Biopsy 532 158 83 859 41 929 125 788
20 009 865 210 432 605 1 297 815
Diagnosed cervical lesions
Treatment with LEEP 309 2 049 633 195 316 598 949 793
VIA positive treated with cryotherapy 1 408 96 169 647 84 823 254 470
Follow up of LSIL with Pap smear 6 months later and antibiotics (3
drugs)
12 862 52 664 995 332 497 997 492
Treatment of HSIL with hysterectomy during anesthesia 1 917 3 941 7 554 366 3 777 183 11 331 549
16 496 9 022 203 4 511 102 13 533 305
Diagnosed with cervical cancer
FIGO I-Ib1 22 6 405 140 899 70 450 211 349
FIGO Ib2-II 22 25 527 561 601 280 800 842 401
FIGO III 110 24 992 2 749 172 1 374 586 4 123 759
FIGO IV 66 23 923 1 578 905 789 453 2 368 358
220 5 030 578 2 515 289 7 545 867
Genital warts
Wart removal with cauterization 116 552 63 997 31 999 95 996
Wart removal with Podophyllotoxin and antibiotics 5 995 161 966 720 483 360 1 450 080
6 111 1 030 717 515 359 1 546 076
Total 42 836 15 948 708 7 974 354 23 923 062
https://doi.org/10.1371/journal.pone.0177762.t005
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of which costs for treatment with radical hysterectomy represented the largest cost of $7.6 mil-
lion in the base case estimate (Table 5).
The total direct medical cost for the cervical screens, management and treatment of cervical
lesions, cervical cancer and genital warts in 2015 was estimated at $16 million in the base case.
To investigate the impact on the result we varied the input variables by ±50% and the total
annual cost estimate ranged between $8 and $24 million. To reflect the number of unrecorded
cases in the public or private hospitals, we increased the prevalence rates by 25% and the costs
were then estimated at $19.9 million (ranged between $10 million and $30 million).
Discussion
This study is the first to estimate the economic burden including the direct medical costs of
HPV-related diseases including precancerous lesions, cervical cancer and genital warts in Swa-
ziland. The largest cost in the analysis-cost was for treatment of high-grade lesions $7.6 million
(ranging between $4.5and $13.5 million) followed by costs for treatment of cervical cancer esti-
mated at $5 million (ranging between $2.5 and $7.5 million). Management of anogenital warts
was estimated at $1 million (ranging between $0.5 million and $1.5 million). The cervical
HPV-related conditions incur a major economic burden worldwide [51]. In countries where
there is organized screening, the major cost represents prevention whilst in countries that lack
screening, costs for management and treatment are larger. In this study, the large cost is esti-
mated for treatment of high-grade lesions and treatment of cervical cancer both requiring
extensive treatments at high costs and is therefore representing 80% of the total costs. Screen-
ing alone only represents a minor cost with 5% of the total costs. Both clinical conditions are
mainly detected when patients seek medical care for symptoms. Organized screening pro-
grams with high population coverage would lead to earlier detection of cervical dysplasia and
cancer and following costs for treatment would then be much lower and a higher percentage
of the total cost would be estimated for screening. However, an organized screening program
is today lacking in Swaziland. We did not estimate cost for the non-cervical HPV-related can-
cers, which also affect males and would increase the total estimated costs significantly.
In the United States with organized screening, cervical cancer and cervical intraepithelial
neoplasia (CIN) are the most costly HPV-related conditions, and are estimated to account for
the direct medical cost of $4.6 billion annually [52]. When the cost of managing anogenital
warts and other oncogenic HPV-associated cancers are included, the total costs rise to $5 bil-
lion per year [52]. According to another study, an increase in the direct medical cost associated
with HPV-related conditions has been noted in the United States; in 2010, the overall annual
direct medical cost of preventing and treating HPV-associated diseases was estimated at $8 bil-
lion [53]. Out of this total cost, the majority of $6.6 billion (82%) represented routine cervical
cancer screening and follow-up, whilst $1 billion (12%) was for cancer (including $0.4 billion
for cervical cancer and $0.3 billion for oropharyngeal cancer); $0.3 billion (3.6%) was for ano-
genital warts and $0.2 billion for recurrent respiratory papilomatosis (RRP) [53]. A study done
in Belgium found that the annual direct medical costs of cervical cancer, cervical dysplasia,
and genital warts combined were estimated at approximately $12 million, with around 60%
and 20% of the costs for cervical cancer and CIN management, respectively [54]. In Germany,
the total annual cost of management of genital warts was estimated at $52.3 million from a
third-party payer perspective (indirect cost excluded) and $57.7 million from the societal per-
spective (indirect costs included), corresponding to an average cost per patient of $570 and
$648, respectively [55]. In France, the costs for HPV-related cancers were estimated according
to the percentage of each cancer type attributable to HPV infection. The total costs were esti-
mated to $253.6 million [56]. The overall costs in men were $114.3 million, driven mainly by
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head and neck cancers ($100.9 million) and in women were $141.4 million, due mainly to
invasive cervical cancer ($89.5 million) [56]. In Italy, the total direct costs associated with the
annual incident cases of the nine HPV-related conditions included in the analysis were esti-
mated to be $564 million [57]. Furthermore, the fraction attributable to HPV 6, 11, 16, and 18
was $310.5 million, accounting for approximately 55% of the total annual burden of HPV-
related disease [57]. Another study performed from a societal perspective in Sweden estimated
costs in 2009 for cervical lesions, cervical cancer and genital warts at $113.7 million, of which
$868 million (76%) were direct medical costs and the majority of the cost for the organized
screening programme [40]. The described studies above demonstrate the diversity of how the
costs are distributed between prevention and treatment as well as between direct and indirect
costs. Guidelines for economic studies differ between countries and costs are presented differ-
ently. However, there are more cost-of-illness studies investigating the costs for HPV related
diseases estimated in western countries than in African countries. This study is therefore
unique and useful to health policy makers for planning and budget decisions within Swaziland.
It is important to foresee the future HPV prevalence infection and related carcinogenesis
among the population to plan for increase in costs for treatment and prevention of HPV
related diseases.
In low-resource countries with a lack of organized screening such as Swaziland, the HPV
vaccine is an effective alternative prevention strategy and may be associated with less direct
medical costs annually than screening and management at the local health care site [58]. The
HPV vaccine has proved a robust immune response to the HPV virus and due to the lack of
organized screening in Swaziland should be used for the prevention of cervical cancer. Cover-
ages above 50% in HPV immunization programs among either young females or males are
suggested to give herd immunity [59]. It is proven that anogenital warts have decreased among
both the vaccinated female population and the unvaccinated male population in countries that
have introduced organized HPV vaccination [60, 61]. To estimate the costs related to HPV
vaccination in Swaziland we used the direct medical costs for the HPV vaccine per dose for
HPV-2 and HPV-4 being $120 and HPV-9 $135 in 2016 prices, respectively, based on the US
Centers for Disease Control and Prevention public sector cost [62]. We then extrapolated the
2007–2030 population projections aligned to the 2016 population estimates for the total of
boys and girls aged 9–12 years to estimate the population size. We then multiplied costs with
population size to estimate the vaccine cost in different population scenarios.
If current national young females and males in Swaziland between 9-12-year-olds should be
offered immunization against HPV with the current recommendation of a 2 dose schedule for
HPV-2, HPV-4 and 3 doses for HPV-9, the estimated direct medical costs would be a one-
time cost of approximately $24 million or $40.6 million with HPV-2, HPV-4 or HPV-9 respec-
tively, following an annual cost estimation including only one birth cohort of females plus
males, of approximately $5.5 million or $9.2 million (with HPV-2, HPV-4 or HPV-9 respec-
tively, offered to 9-year-olds), annually based on the number of individuals in each year group
(Table 6). Only including pre-adolescent females would result into a cost estimate of $ 11.8
million and 20 million with HPV-2,HPV-4 and HPV-9 respectively, for all 9-12-year-olds
females and an annual cost of $2.7 and $4.6 million respectively (9-year-old girls). Logistics
and administration of the vaccine would be an added cost to this estimate.
Since oncogenic HPV types also cause a several significant diseases in both females and
males, namely cancer of the vulva, vagina, anus, penis and oropharynx [63] public investment
in vaccination of young females and males is therefore suggested to decrease the public health
care costs and human burden in the next generations. A study from Australia showed a signifi-
cant decrease in the prevalence of vaccine-targeted HPV types, possible cross-protective effects
in the same vaccinated group and herd immunity among the unvaccinated females [64].
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Another study from Scotland observed a similar reduction in HPV in the unvaccinated popu-
lation, but the effect of herd immunity is difficult to fully establish due to a continuous smaller
number of unvaccinated females in countries with national immunization programmes [65].
To exclude males from HPV immunization programmes, a coverage of 80% is suggested to
establish herd immunity among the unvaccinated population [66]. The reduction in the preva-
lence of HPV infection should reduce the number of cervical lesions, cervical cancer and geni-
tal warts over time, with subsequently reduced needs in management and treatment, and the
future reduction in the human and economic burden of HPV-related diseases and related
deaths due to HPV-related cancers.
Even though costs presented in this study are substantial, it is likely to be a major underesti-
mation of actual costs. Important limitations of this study are that it only included costs related
to the direct medical health care costs and excluded the costs for the patients. In addition, palli-
ative care occurring outside a hospital setting, or other costs like patient transportation were
also excluded. Informal care from family members was also excluded and this is expected to
impact on the cost estimations. Indirect costs (i.e., lost productivity due to illness) were also
excluded, which could lead to an underestimation of the societal benefits in making decision
about public interventions such as HPV immunization. Costs for adverse outcomes such as
preterm births associated with treatment of cervical lesions and decreased quality of life associ-
ated with the cervical HPV-related diseases, were excluded in this study. A further economic
analysis should therefore include the societal costs (including both direct and indirect costs)
for all known HPV-related illnesses to present the total cost of HPV-related diseases for both
sexes. Such as estimate would then reflect the total HPV-related economic burden for the soci-
ety in countries that have implemented an HPV immunization program, there is an expected
decrease in HPV-related conditions in future generations. To guide public health policy in
Swaziland, a cost-effectiveness analysis (CEA) projecting both health and economic outcomes
in “real life scenarios”, should be performed. The CEA should include all costs from HPV-
related conditions and benefits from HPV vaccination for both sexes to evaluate the allocation
of resources for a national HPV immunization program among the pre-adolescents.
Conclusions
The economic burden of HPV-related cervical diseases and genital warts represents a major
public health issue in Swaziland. Prevention of HPV infection with a national HPV immuniza-
tion program for pre-adolescents would prevent the majority of HPV-related conditions and
the related deaths. Large cost savings would then result for public health care resources utilized
Table 6. The 2007–2030 population projections aligned to the 2016 population (estimates total of
boys and girls aged 9–12 years) and vaccine costs presented in $ 2015.
Ages Boys Girls Total HPV-2, 4 cost ($)* HPV-9 cost ($)**
9 11 518 11 242 22 760 5 462 400 9 217 800
10 12 825 12 328 25 153 6 036 720 10 186 965
11 13 244 12 791 26 035 6 248 400 10 544 175
12 13 283 12 962 26 245 6 298 800 10 629 225
Total 50 870 49 323 100 193 24 046 320 40 578 165
*Cost estimation with 2 doses schedule as current recommendations for HPV-2, 4.
** Cost estimation with 3 doses schedule as current recommendation for HPV-9.
Source: Swaziland population projections 2007–2030 [46]
https://doi.org/10.1371/journal.pone.0177762.t006
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for the management and treatment of cervical lesions, cervical cancer and genital warts in
Swaziland.
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